Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early-stage NSC… Recruiting

2024-516580-87-00 early stage NSCLC 9 2024-10-29
Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed b… Recruiting

2024-518143-38-00 Metastatic pancreatic cancer 10 2024-10-25
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting

2024-513219-29-00 Renal Cell Carcinoma 5 2024-10-21
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants with Relapsed or Refractory (R/R) Chronic… Recruiting

2023-507637-19-00 Small Lymphocytic Lymphoma 3 2024-10-15
An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study Recruiting

2024-512217-40-00 Malignant Solid Tumors 10 2024-10-11
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting

2024-511404-17-00 Unresectable or metastatic NRAS mutant cutaneous melano 5 2024-10-07
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4… Recruiting

2022-502825-17-00 Melanoma 4 2024-10-07
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 10 2024-10-02
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting

2023-504445-31-00 Carcinoma, Head and Neck 4 2024-09-19
A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno… Recruiting

2023-510422-32-00 Tenosynovial Giant Cell Tumour 5 2024-09-10
Improving the empowerment in patients with severe breast fibrosis radio-induced treated by Pravastatin : benefit of e-PROs (electronic « Pat… Recruiting

2024-515342-16-00 Patients with severe and radio-induced breast fibrosis 4 2024-09-05
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Recruiting

2023-506227-29-00 locally advanced or metastatic solid tumors 3 2024-08-30
A Study to see how safe is RO7567132 as Single Agent and in Combination with Atezolizumab, how the body gets rid of it and how effective it … Recruiting

2024-512839-70-00 Advanced and/or Metastatic Solid Tumors 1 2024-08-27
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting

2023-507555-29-00 LA/mGC/GEJC (locally advanced unresectable or metastati 9 2024-08-16
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion Recruiting

2024-515456-20-00 Hepato carcinoma cancer 4 2024-08-13
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 gastroesophageal junction adenocarcinoma 9 2024-08-05
Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting

2022-501105-12-00 Urothelial Carcinoma 5 2024-07-15
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relap… Recruiting

2023-507901-32-00 Relapsed or Refractory Multiple Myeloma (R/R MM) 3 2024-06-28
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
Evaluation of the omission of dexamethasone in premedication regimens during paclitaxel treatment Recruiting

2023-507481-43-00 Solid tumors 11 2024-06-25
A Study of Disitamab Vedotin Alone or with Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting

2022-500030-28-01 Urothelial carcinoma 4 2024-06-10
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 non-squamous non-small cell lung cancer 5 2024-06-06